Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Carlos Vila Silván
Observed names:
C. Vila Silván,
Carlos Vila Silvan,
Silván, Carlos Vila
Institution:
Almirall (Spain)
Observed institution:
Almirall (Spain)
ORCID:
0000-0001-5541-7848
Observed ORCID:
0000-0001-5541-7848
OpenAlex ID:
A5058239803
A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’
2022
·
Francesco Patti
, Clara Grazia Chisari
, et al.
·
European Journal of Neurology
·
29
PDF
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial
2020
·
Sven G Meuth
, Thomas Henze
, et al.
·
International Journal of Neuroscience
·
29
Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years” accumulated evidence from clinical trials
2021
·
José María Prieto González
, Carlos Vila Silván
·
Expert Review of Neurotherapeutics
·
24
A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis
2022
·
Francisco Javier Carod-Artal
, Peyman Adjamian
, et al.
·
Expert Review of Neurotherapeutics
·
16
Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry
2021
·
Michael A Ueberall
, Carlos Vila Silván
, et al.
·
Pain Medicine
·
16
PDF
Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports
2021
·
José María Prieto González
, Carlos Vila Silván
·
Expert Review of Neurotherapeutics
·
15
Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity
2021
·
Antonella Conte
, Carlos Vila Silván
·
Neurodegenerative Diseases
·
15
Evidence-based Management of Multiple Sclerosis Spasticity With Nabiximols Oromucosal Spray in Clinical Practice: A 10-year Recap
2022
·
Andrew Chan
, Carlos Vila Silván
·
Neurodegenerative Disease Management
·
14
Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses
2021
·
Mark Oppe
, Daniela Ortín-Sulbarán
, et al.
·
The European Journal of Health Economics
·
5
PDF
Effect of Nabiximols On Goal Attainment Scale Scores in Patients With treatment-resistant Multiple Sclerosis Spasticity
2021
·
Friedemann Paul
, Carlos Vila Silván
·
Neurodegenerative Disease Management
·
5
Systematic reviews of randomized controlled trials of cannabinoid products in chronic pain conditions and for symptoms associated with multiple sclerosis: what do they tell us?
2022
·
Carlos Vila Silván
, Claude Vaney
, et al.
·
Expert Review of Clinical Pharmacology
·
1
Pnd86 Cost-utility Analysis of Delta-9-tetrahidrocannabinol and Cannabidiol Oromucosal Spray
2019
·
M. Oppe
, D. Ortín-Sulbarán
, et al.
·
Value in Health
·
1
PDF
Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing
2019
·
Paloma Montero-Escribano
, Carlos Vila Silván
·
Expert Review of Medical Devices
·
1
A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols
2023
·
Clara Grazia Chisari
, Joe Guadagno
, et al.
·
Therapeutic Advances in Neurological Disorders
Show more works
View as search
Works count:
16
Citation count:
171
H-index:
8
I10-index:
8
Year
Topic
Type
